Navigation Links
Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
Date:9/1/2010

SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the Company will present at the following investor conferences:

  • Robert W. Baird 2010 Health Care Conference on Tuesday, September 14, 2010 at 8:30 a.m. Eastern Time at The St. Regis Hotel in New York City.
  • UBS Global Life Sciences Conference 2010 on Tuesday, September 21, 2010 at 10:00 a.m. Eastern Time at the Grand Hyatt New York in New York City.
  • 5th Annual JMP Securities Healthcare Conference on Monday, September 27, 2010 at 9:00 a.m. Eastern Time at The New York Palace in New York City.

  • (Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

    (Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

    Live audio webcasts of these presentations will be accessible on the Company's website at www.optimerpharma.com, under the investors section.  Replays of these presentations will be available at the same location for 30 days after the presentations.

    About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI).  In two Phase 3 trials completed by Optimer to study the safety and efficacy of fidaxomicin for the treatment of CDI, fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) and reduced recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea.  Optimer has also successfully completed two Phase 3 trials with Pruvel.  Additional information can be found at http://www.optimerpharma.com.ContactsOptimer Pharmaceuticals, Inc.Christina Donaghy, Corporate Communications ManagerJohn D. Prunty, Chief Financial Officer & VP Finance858-909-0736Canale Communications, Inc.Jason I. Spark, Senior Vice President619-849-6005
    '/>"/>

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
    2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
    3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
    4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
    5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
    6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
    7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
    8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... 2017 operating results on Monday, August 7, 2017 after ... 5:00 p.m. ET. ... broadcast of the conference call by dialing 877-201-0168 or ... approximately 15 minutes prior to the call. A live ...
    (Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
    (Date:7/21/2017)... , July 21, 2017 Did you know that ... in 2016? Or that combined spending on brand medicines, generics and ... spending, with brands accounting for just half of this (7 percent)? ... two thirds of the world,s venture capital investments in high-growth biopharmaceutical ... ...
    Breaking Medicine Technology:
    (Date:7/27/2017)... ... July 27, 2017 , ... ... 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s ... the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, ...
    (Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners ... their continued efforts to provide innovative offerings to their healthcare partners. These solutions ... build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent ...
    (Date:7/26/2017)... ... ... time to sign up for the new One-A-Month Essential Oil Club for fun and ... Naturals and author of numerous books on essential oils. , , ... , Two items are included in the December mailing. , A ...
    (Date:7/26/2017)... Michigan (PRWEB) , ... July 26, 2017 , ... ... appointed Medical Director for the treatment program located in Royal Oak, Michigan. ... of investors who are focused on providing the highest standards in the field of ...
    (Date:7/26/2017)... ... 2017 , ... The number of adults 65 years or older is expected ... asthma control in the population are not well described. In a study published in ... journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors ...
    Breaking Medicine News(10 mins):